Cas.no | PubChem ID |
65271-80-9 | 4212 |
Known Target | |
DNA | |
DNA topoisomerase 2-alpha | P11388 |
Structure | |
![]() |
|
Introduction | |
Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity. |
Cas.no | PubChem ID |
879085-55-9 | 24776445 |
Known Target | |
Smoothened homolog | Q99835 |
Structure | |
![]() |
|
Introduction | |
Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). It acts as a cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part of the hedgehog signaling pathway. SMO inhibition causes the transcription factors GLI1 and GLI2 to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway. This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas. |